2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150CJC-1295 without DAC (Drug Affinity Complex) is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH) designed to enhance pulsatile growth hormone (GH) secretion [1].
CJC-1295 is a modified 30-amino-acid fragment of native GHRH that incorporates substitutions at positions 2, 8, 15, and 27, to increase stability.
Because GH secretion is tightly rhythm-regulated, particularly during sleep, preserving this pulsatile pattern can support metabolic, muscular, and regenerative functions.
Because GH secretion naturally occurs in rhythmic bursts, especially during deep sleep, CJC-1295 without DAC preserves this pattern rather than producing continuous elevation [2].
Once GH is released, it stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1). IGF-1 mediates many of GH’s downstream actions, including [3]:
By amplifying both GH and IGF-1 signaling, CJC-1295 without DAC acts as a dual-phase secretagogue.
Two randomized, double-blind, placebo-controlled dose ascending trials of healthy adults (over 28 and 49 days, respectively), characterized the profile of CJC-1295 [4].
In the first trial, participants received one of four ascending single subcutaneous doses of CJC-1295 or placebo. In the second trial, participants received two or three weekly or biweekly injections.
Results showed that:
No serious adverse events or trial withdrawal were reported across either study.
CJC-1295 without DAC amplifies natural pulsatile GH release, creating a metabolic environment that supports gradual, physiologic recomposition.
Key mechanisms underlying these effects include [5]:
A GHRH gene–ablated (GHRHKO) mice was studied to determine whether CJC-1295 can normalize growth and body composition in the absence of endogenous GHRH [5].
Over 5 weeks, mice were split into the following treatment groups:
Results showed that:
This study highlights the therapeutic potential of CJC-1295 in severe GHRH deficiency and underscores the importance of dosing frequency in achieving full physiologic restoration.
CJC-1295 without DAC may support tissue repair and recovery from musculoskeletal injury through its influence on growth hormone–mediated regenerative pathways [6].
Because GH and IGF-1 play roles in:
enhancing their natural pulsatile release can create a biochemical environment favorable for healing.
Key mechanisms underlying these effects include:
Currently, no robust studies exist that investigate these potential effects.
CJC-1295 without DAC offers a distinct therapeutic profile shaped by its shorter half-life and physiologic mimicry of natural growth hormone secretion.
Mimics Natural GH Physiology
Because CJC-1295 without DAC delivers pulsatile GH stimulation, this can reduce the risk of GH receptor desensitization.
Lower Risk of Side Effects
Pulsatile secretagogues tend to cause fewer adverse effects such as:
The intermittent stimulation gives metabolic pathways time to normalize between pulses.
Better Control Over Timing
Users and clinicians can schedule injections around sleep cycles, fasting windows, or training sessions to optimize GH peaks.
Requires More Frequent Injections
Because the peptide is rapidly cleared, achieving meaningful GH pulses may require one to three injections daily. This can reduce convenience and adherence compared to once-weekly DAC formulations.
Shorter Therapeutic Window
Missed doses or inconsistent scheduling can significantly affect outcomes, as the peptide’s benefits depend on steady, rhythmic stimulation.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). CJC-1295 No DAC is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 6-panel testing protocol: identification by ESI-MS, purification by RP-HPLC, conformity, sterility screening, quantification of net peptide content, and LAL endotoxin screening. Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders are processed within 1–3 business days after payment confirmation. Orders placed after 3:00 PM Pacific time or on weekends and holidays will begin processing the next business day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and quantification data where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 100+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
What is CJC 1295 with DAC? CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic analogue of growth hormone–releasing hormone (GHRH) engineered to extend the duration of pulsatile growth hormone (GH) stimulation [1]. While short-acting GHRH analogues mimic the body’s natural rhythm in brief intervals, the DAC modification enables CJC-1295 to bind covalently to circulating albumin, dramatically increasing its half-life and sustaining its physiologic influence for days rather than hours [2]. This stability allows for consistent signaling through the GH–IGF-1 axis, which plays a central role in growth, tissue maintenance, and metabolic regulation [3]. This 30 amino acid peptide retains features of native GHRH but incorporates amino-acid substitutions that enhance resistance to enzymatic breakdown. When combined with DAC, these modifications create a formulation capable of maintaining elevated IGF-1 levels with infrequent administration. CJC-1295 can provide extended support to endocrine pathways involved in cellular repair, lean-mass maintenance, and metabolic homeostasis. CJC 1295 with DAC benefits and advantages Prolonged elevation of GH and IGF-1 The DAC modification helps the peptide to form a stable covalent bond with serum albumin, significantly prolonging its half-life compared to non-DAC formulations. This prolonged activity allows for more sustained elevations in circulating IGF-1, a key mediator of anabolic and metabolic processes. IGF-1 plays essential roles in protein synthesis, cellular repair, mitochondrial function, and nutrient partitioning. By maintaining higher IGF-1 concentrations over several days, CJC-1295 with DAC provides a longer, smoother signaling window that may enhance the body’s ability to support tissue maintenance and energy balance. While short-acting GHRH analogues rely on frequent dosing to achieve measurable changes, the DAC-bound version generates a more gradual and durable physiological response. This extended profile can: Reduce fluctuations Minimize peaks and troughs While preserving the rhythmic qualities of GH secretion and broadening the duration of downstream effects. An interventional clinical study of healthy adult men evaluated the effects of CJC-1295 on GH secretion parameters [4]. Participants received either 60 μg/kg or 90 μg/kg of a single subcutaneous injection of CJC-1295 with DAC. Participants then underwent 20-minute interval blood sampling over 12 hours overnight to characterize GH pulsatility. Results showed that: GH Secretion Increased without disrupting pulsatility Basal GH increased 7.5-fold (p < 0.0001) Mean GH levels increased by 46% (p < 0.01) IGF-1 IGF-1 levels increased by 45% (p < 0.001) 60 μg/kg vs 90 μg/kg showed no significant difference in GH or IGF-1 effects. A single dose of CJC-1295 significantly increases basal (trough) GH secretion, leading to higher mean GH and IGF-1 levels, while keeping pulsatility intact. Body composition and muscle growth benefits CJC-1295 with DAC’s extended influence on the GH–IGF-1 axis can create a metabolic and anabolic environment that supports favorable shifts in body composition. Growth hormone plays a central role in nutrient partitioning, encouraging the body to utilize fat as an energy substrate while preserving lean tissue. Through its prolonged stimulation of GH release and sustained elevation of IGF-1, CJC-1295 with DAC can reinforce pathways associated with [5]: Muscle protein synthesis Connective-tissue turnover Recovery from mechanical stress IGF-1 is particularly significant in this context, as it is involved in regulating: Satellite cell activation [6] Collagen formation [7] Structural remodeling within muscle fibers By maintaining more consistent IGF-1 levels over time, CJC-1295 with DAC may help the body support muscle maintenance and gradual increases in lean mass, especially when combined with resistance training or periods of heightened physical demand. Currently however, no human trials exist that evaluate these potential effects. A previous study did attempt to characterize whether CJC 1295 can reduce visceral fat in HIV patients with pathologic lipodystrophy [8]. However, after the death of a participant due to HIV itself, the trial was discontinued, with no data published. Although there is some volume of anecdotal evidence of online users self-administering CJC 1295 for weight loss, regulated human studies need to be established to validate these theoretical applications.
Overview CJC-1295 (no DAC) + GHRP-2 leverages complementary growth hormone (GH) axis stimulations through distinct receptor mechanisms. These peptides can engage two distinct upstream regulatory pathways that influence endogenous GH release. Combined, they can provide a model for evaluating dual-pathway stimulation of pituitary activity, pulsatile hormone dynamics, and downstream metabolic signalling. What is CJC-1295 without DAC? CJC--1295 without DAC (also called Mod GHF1-29) is a synthetic and chemically modified form of growth hormone–releasing hormone (GHRH) without containing the drug affinity complex (DAC) [1]. This dramatically shortens the peptide's half-life, thus more closely mimicking the natural pulsatile endogenous GHRH secretion. It produces a brief rise in growth hormone (GH) and insulin growth factor-1 that clears quickly from circulation rather than prolonged stimulation. In contrast, when CJC-1295 with DAC binds to albumin, it can persist for multiple days, thereby sustaining GHRH receptor stimulation [1]. CJC-1295 without DAC is structurally derived from GRF(1-29), the biologically active component of GHRH [2, 3]. Unlike sermorelin, which has natural amino acids, CJC-1295 without DAC has stabilizing substitutions, including D-amino modifications at position 2. As a result, this version of CJC-1295 resists dipeptidyl peptidase-4 degradation and has prolonged activity while preserving receptor affinity [2, 3]. This is thought to shorten exposure time, reduce the risk of receptor desensitization, and avoid chronically elevated baseline GH. Because it acts and clears quickly, it can be timed around sleep when GH naturally peaks and paired strategically with a GHRP that offers easier dosing adjustments. What is GHRP-2? Growth Hormone Releasing Peptide-2 (GHRP-2) is a synthetic ghrelin receptor agonist peptide [4]. It mimics the action of the gut-derived hormone ghrelin, which influences hunger [4]. Ghrelin naturally binds to the growth hormone secretagogue receptor GHS-R1a. GHS-R1a is found in both the pituitary gland and the hypothalamus [4]. GHRP-2 was developed as a research compound to stimulate growth hormone secretion through this ghrelin pathway [4]. CJC-1295-GHRP2 Synergy Both GHRP-2 and CJC-1295 stimulate GH secretion through two distinct, yet complementary, receptor pathways [1, 4]. GHRP-2 activates ghrelin receptor GHS-R1a, engaging calcium-mediated signalling that promotes acute GH release [5]. When GHRP-2 binds to GHS-R1a in the pituitary, GHRP-2 stimulates growth hormone release in a pulsatile manner [6]. Whereas, in the hypothalamus, GHRP-2’s binding to GHS-R1a activates appetite pathways [6]. Unlike CJC-1295 or other GHRH analogs, GHRP-2 activates a different intracellular pathway involving Gq/11 signalling, calcium influx, and amplification of GH secretion [7]. This allows GHRP-2 to work synergistically with GHRH analogs. In contrast, CJC-1295 acts at the GHRH receptor to enhance cAMP-mediated GH synthesis and secretion [2]. Combined, this dual-pathway stimulation is hypothesized to support both the amplitude and duration of GH secretion, potentially preserving physiologic pulsatility while extending the overall GH exposure window. Both GHS-R1a and GHRH analog converge on pituitary somatotroph activation. GHRP-2 predominantly drives PKC/Ca2+-linked signalling that amplifies secretory output, whereas GHRH receptor signalling is cAMP/PKA-mediated, supporting GH synthesis and release. In vitro studies show that combined GHRH and CHRP-2 increase GH release and transcriptional signaling more than either alone, suggesting dual-pathway synergistic effects [8]. in vivo and clinical evidence also confirm that the combination of GHRH and GHRP-2 produces stronger growth hormone responses [9, 10]. Human studies using GHRH(1-29) in combination with GHRP-2 show greater GH increases than with single-peptide administration [9]. In hypogonadal men, GHRP-2 administration alone can induce up to 47-fold GH increase, and up to 54-fold increase when combined with GHRH [11]. Animal studies show similar results, with combined stimulation leading to significantly amplified GH release [10]. Dosage and Ratio Considerations The combined formula, using similar potencies, is geared toward balancing receptor engagement. Because both peptides act on different but complementary pathways, using equivalent doses may provide proportional activation of both the GHRH receptor and the ghrelin receptor. References: 1 Ionescu, M. and Frohman, L. A. (2006) Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J. Clin. Endocrinol. Metab., The Endocrine Society 91, 4792–4797 2 Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., et al. (2005) Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, The Endocrine Society 146, 3052–3058 3 Scarborough, R., Gulyas, J., Schally, A. V. and Reeves, J. J. (1988) Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine. J. Anim. Sci., Oxford University Press (OUP) 66, 1386–1392 4 Laferrère, B., Abraham, C., Russell, C. D. and Bowers, C. Y. (2005) Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J. Clin. Endocrinol. Metab., The Endocrine Society 90, 611–614 5 Ghigo, E., Arvat, E., Muccioli, G. and Camanni, F. (1997) Growth hormone-releasing peptides. Eur. J. Endocrinol., Oxford University Press (OUP) 136, 445–460 6 Bowers, C. Y., Momany, F. A., Reynolds, G. A. and Hong, A. (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, The Endocrine Society 114, 1537–1545 7 Gondo, R. G., Aguiar-Oliveira, M. H., Hayashida, C. Y., Toledo, S. P., Abelin, N., Levine, M. A., et al. (2001) Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. J. Clin. Endocrinol. Metab., The Endocrine Society 86, 3279–3283 8 Yan, M., Hernandez, M., Xu, R. and Chen, C. (2004) Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells. Eur. J. Endocrinol., Oxford University Press (OUP) 150, 235–242 9 Bowers, C. Y. and Granda-Ayala, R. (1996) GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J. Pediatr. Endocrinol. Metab., J Pediatr Endocrinol Metab 9 Suppl 3, 261–270 10 Argente, J., García-Segura, L. M., Pozo, J. and Chowen, J. A. (1996) Growth hormone-releasing peptides: clinical and basic aspects. Horm. Res., S. Karger AG 46, 155–159 11 Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., et al. (2020) Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl. Androl. Urol., AME Publishing Company 9, S149–S159
Snapshot CJC-1295 No DAC (GHRH analog) and GHRP-6 (ghrelin receptor agonist) stimulate endogenous GH via complementary cAMP and Ca²⁺ signaling pathways. Preclinical and clinical GHRH+GHS studies demonstrate synergistic GH release compared to either alone, supporting dual-pathway activation of the somatotroph axis in research settings. CJC-1295 No DAC CJC-1295 No DAC is a modified analog of growth hormone–releasing hormone designed to stimulate endogenous growth hormone (GH) secretion by activating GHRH receptor (GHRH-R) on anterior pituitary somatotrophs. This “No DAC” version does not contain the albumin-binding component, resulting in a shorter half-life and a more physiologic, pulse-like stimulation of GH release. CJC-1295 No DAC activates the adenylyl cyclase–cAMP–protein kinase A (PKA) pathway following GHRH-R binding. This signaling cascade promotes transcription and secretion of GH, which then increases circulating insulin-like growth factor-1 (IGF-1) through hepatic stimulation [1]. By amplifying endogenous pulsatile GH release rather than replacing GH directly, CJC-1295 without DAC preserves feedback regulation via somatostatin and IGF-1. GHRP-6 GHRP-6 (growth hormone–releasing peptide-6) is a synthetic hexapeptide classified as a growth hormone secretagogue (GHS). It stimulates endogenous GH release by binding to the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. GHRP-6 specifically stimulates hunger more than GHRP-2, which may be more beneficial for weight gain. Unlike GHRH analogs, GHRP-6 activates a distinct signaling pathway. After binding to GHS-R1a, it stimulates the phospholipase C (PLC)–inositol triphosphate (IP3)–calcium pathway, increasing intracellular calcium and GH secretion from anterior pituitary somatotrophs [2]. This mechanism is independent of the cAMP pathway used by GHRH. Synergy CJC-1295 No DAC (a GHRH analog) and GHRP-6 (a ghrelin/GHS receptor agonist) can be paired because they stimulate endogenous growth hormone (GH) release through distinct, convergent control pathways: CJC-1295 without DAC works via GHRH receptor–adenylyl cyclase–cAMP signaling. GHRP-6 activates GHS-R1a and triggers a PLC/IP3/Ca²⁺-linked secretory pathway. This dual-pathway stimulation can increase GH pulse amplitude and responsiveness without relying on a single upstream signal. A key mechanistic finding supporting “synergy” is that ghrelin/GHS receptor activation can potentiate GHRH-driven signaling. In a cell study expressing cloned GHRH and GHS receptors, ghrelin/GHS compounds alone did not increase cAMP, but co-activation of GHS and GHRH receptors produced a cAMP response approximately 2x higher than GHRH alone, suggesting receptor-level cross-talk [3]. Complementary pituitary cell work also describes cross-talk between PKC-linked signaling and the cAMP/PKA axis during GRF/GHRP stimulation. One pathway supplies the canonical “drive” signal, while the other increases secretory gain and somatotroph excitability. Evidence in the Literature Direct, peer-reviewed clinical studies explicitly testing CJC-1295 No DAC with GHRP-6 together are currently lacking. While published studies typically evaluate GHRH + GHRP-6 (rather than CJC-1295 specifically), the physiology is directly relevant because CJC-1295 is a GHRH-receptor agonist. Therefore, these published results may be extrapolated to explain the benefits of CJC-1295 combined with GHRP-6. Human endocrine studies have repeatedly shown that co-administration of GHRH and GHRP-6 elicits larger GH responses than either secretagogue alone [4]. A clinical study evaluated growth hormone (GH) responses to GHRP-6 (90 μg IV), GHRH (100 μg IV), and combined GHRP-6 + GHRH in 21 patients with non–insulin-dependent diabetes mellitus (NIDDM). Patients were divided into three groups: Group A: Normal weight Group B: Overweight Group C: 8 normal-weight healthy controls Each participant received all three stimulation tests on separate occasions. Results showed that: There was no significant difference in GH when given just GHRP-6 in all 3 groups. Overweight individuals had a significant impairment in GH levels when given GHRH alone compared to control and normal weight individuals (p < 0.05). GH was synergistically and significantly increased when participants received the combined GHRP-6 and GHRH (p < 0.05). The impaired response to GHRH in overweight diabetics can be partially overridden by GHRP-6, consistent with dual-pathway mechanisms. The study provides clinical evidence for synergistic GH stimulation when GHRP-6 and GHRH are co-administered. Comments on Dosage A balanced 1:1 mass ratio (5 mg + 5 mg) can be described conceptually as aiming to equally engage both upstream control systems, GHRH-R (cAMP/PKA) and GHS-R1a (Ca²⁺-linked signaling), to maximize complementary pathway activation rather than over-weighting a single mechanism. Beyond that general logic, optimal ratios are not established in publicly available combination studies and should be treated as empirical parameters. References: 1 Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P. and Frohman, L. A. (2006) Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J. Clin. Endocrinol. Metab. 91, 799–805 2 Oliveira, J. H. A., Vieira, J. G. H., Abucham, J. and Lengyel, A. M. J. (2003) GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing’s disease: comparison with DDAVP. J. Endocrinol. Invest., Springer Science and Business Media LLC 26, 230–235 3 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582 4 Micić, D., Macut, D., Popović, V., Kendereski, A., Sumarac-Dumanović, M., Zorić, S., et al. (1999) Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus. Metabolism, Elsevier BV 48, 525–530